Across TCGA pan-cancer cohorts, HEXIM1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HEXIM1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HEXIM1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HEXIM1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, HNSC, and OV are the cancer types where HEXIM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.420	0.892	<.001	49	view →
HNSC	DFS	Median	All	0.361	0.895	.007	24	view →
OV	DFS	Median	All	0.647	0.913	.047	4	view →
GBM	OS	Median	All	0.486	0.296	.032	4	view →
LSCC	OS	Median	All	0.812	0.922	.031	4	view →
CCRCC	DFS	Tertile	All	0.669	1.000	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: HEXIM1 tumor-vs-normal RNA expression · all HEXIM1 data types